Cargando…
Advances in anti-fungal therapies
Anti-fungal therapies remain sub-optimal, and resistant pathogens are increasing. New therapies are desperately needed, especially options that are less toxic than most of the currently available selection. In this review, I will discuss anti-fungal therapies that are in at least phase I human trial...
Autor principal: | Waterer, Grant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280599/ https://www.ncbi.nlm.nih.gov/pubmed/34268702 http://dx.doi.org/10.1007/s11046-021-00560-2 |
Ejemplares similares
-
Advances in community-acquired pneumonia
por: Jones, Barbara, et al.
Publicado: (2020) -
Breathing Hope into Directed Therapy for Pulmonary Infections
por: Waterer, Grant
Publicado: (2021) -
What is pneumonia?
por: Waterer, Grant
Publicado: (2021) -
Choosing the right combination therapy in severe community-acquired pneumonia
por: Waterer, Grant W, et al.
Publicado: (2006) -
Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection
por: Gleeson, Laura E., et al.
Publicado: (2022)